A LOWER DOSAGE OF IMATINIB IS SUFFICIENT TO MAINTAIN UNDETECTABLE DISEASE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WITH LONG-TERM LOW-GRADE TOXICITY OF THE TREATMENT

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F16%3A33154292" target="_blank" >RIV/61989592:15110/16:33154292 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.3109/10428194.2015.1056184" target="_blank" >http://dx.doi.org/10.3109/10428194.2015.1056184</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/10428194.2015.1056184" target="_blank" >10.3109/10428194.2015.1056184</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A LOWER DOSAGE OF IMATINIB IS SUFFICIENT TO MAINTAIN UNDETECTABLE DISEASE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WITH LONG-TERM LOW-GRADE TOXICITY OF THE TREATMENT

Popis výsledku v původním jazyce

The information about chronic myeloid leukemia (CML) patients with a deep molecular response of GREATER-THAN OR EQUAL TO 4.5 log reduction (MR4.5) in whom the dose of imatinib (IM) had to be reduced to relieve toxicity is insufficient. In 205 CML patients the dose of IM was reduced in 19 (31.2%) out of 61 patients with MR4.5. The patients (12 pretreated with interferon-alpha) achieved MR4.5 after an average of 27.7 months. The duration of MR4.5 before the reduction of the dose was 16-123 (mean = 56.7) months. After the IM reduction (200 mg daily to 400 mg twice weekly for 15-90 (mean = 48) months) MR4.5 or major molecular response (MMR) was maintained in 14 (73.7%) and 2 (10.5%) patients, respectively. Three patients who lost MMR (15.8%) after the discontinuation of IM regained MR4.5 after the reintroduction of a lower dose. A lower dosage of IM should be tested for the management of side effects in patients with MR4.5 in prospective studies.

Název v anglickém jazyce

A LOWER DOSAGE OF IMATINIB IS SUFFICIENT TO MAINTAIN UNDETECTABLE DISEASE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WITH LONG-TERM LOW-GRADE TOXICITY OF THE TREATMENT

Popis výsledku anglicky

The information about chronic myeloid leukemia (CML) patients with a deep molecular response of GREATER-THAN OR EQUAL TO 4.5 log reduction (MR4.5) in whom the dose of imatinib (IM) had to be reduced to relieve toxicity is insufficient. In 205 CML patients the dose of IM was reduced in 19 (31.2%) out of 61 patients with MR4.5. The patients (12 pretreated with interferon-alpha) achieved MR4.5 after an average of 27.7 months. The duration of MR4.5 before the reduction of the dose was 16-123 (mean = 56.7) months. After the IM reduction (200 mg daily to 400 mg twice weekly for 15-90 (mean = 48) months) MR4.5 or major molecular response (MMR) was maintained in 14 (73.7%) and 2 (10.5%) patients, respectively. Three patients who lost MMR (15.8%) after the discontinuation of IM regained MR4.5 after the reintroduction of a lower dose. A lower dosage of IM should be tested for the management of side effects in patients with MR4.5 in prospective studies.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia &amp; Lymphoma

ISSN

1042-8194

e-ISSN

—

Svazek periodika

57

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

370-375

Kód UT WoS článku

000368511800021

EID výsledku v databázi Scopus

—